Drugs / TI-0093
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07081984 | Nov 2025 → Sep 2026 overdue | cervical cancer, head and neck squamous cell carcinoma, human papillomavirus-related squamous cell carcinoma | Therorna | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-01-13 | Therorna | Results 圆因生物HPV相关癌症环状RNA治疗性疫苗临床前数据重磅发布，展现卓越抗肿瘤潜力 therorna.com ↗
治疗性复发模型数据进一步显示，接受 circRNA E7E6 疫苗干预的 10 只小鼠，均在 21 天内实现肿瘤完全消退。 |
| 2025-08-22 | Therorna | Regulatory 圆因生物环状 RNA 药物获批临床，开启肿瘤免疫治疗新纪元 therorna.com ↗
2025 年 8 月 22 日，国家药品监督管理局药品审评中心（ CDE ）官网公示显示： 圆因生物自主研发的环状 RNA 药物 TI-0093 注射液的新药临床试验（ IND ）申请获得临床试验默示许可。 |
| 2025-06-11 | Therorna | Regulatory 圆因生物环状RNA药物IND申报获CDE受理 therorna.com ↗
2025年 6 月 6 日，据国家药品监督管理局药品审评中心（ CDE ）官网公示， 圆因生物环状 RNA 药物 TI-0093 注射液临床试验（ IND ）申请获得受理（受理号： CXSL2500461 ）。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-13 | Therorna | 圆因生物HPV相关癌症环状RNA治疗性疫苗临床前数据重磅发布，展现卓越抗肿瘤潜力 therorna.com ↗ |
| 2025-08-22 | Therorna | 圆因生物环状 RNA 药物获批临床，开启肿瘤免疫治疗新纪元 therorna.com ↗ |
| 2025-06-11 | Therorna | 圆因生物环状RNA药物IND申报获CDE受理 therorna.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TI-0093 | “TI-0093 injection will be administered intramuscularly on Day1, Day8, Day15, Day29 and Day43.” NCT07081984 ↗ |
| Modality | Vaccine | “Therapeutic tumor vaccine: TI-0093 injection.” NCT07081984 ↗ |
| Route | Intramuscular | “TI-0093 injection will be administered intramuscularly on Day1, Day8, Day15, Day29 and Day43.” NCT07081984 ↗ |